Sobi Q3 2026 report: Underpinning a strong growth momentum

Sobi’s Q3 2026 revenue rose 16% at constant exchange rates (CER) and 17% at actual rates to SEK 9,124 million, with year-to-date CER growth of 23%. Haematology revenue increased 29% at CER to SEK 6,171 million, while immunology revenue declined 6% to SEK 2,525 million.

Analysis

The key read-through is product mix, not the headline growth rate: incremental growth is being carried by a small number of haematology franchises while immunology is contracting. That can support near-term earnings momentum, but also raises the bar for sustained uptake and makes quarterly results more sensitive to launch trajectory, access, and product-level competition. Altuvoct’s factor-replacement market faces substitution pressure from non-factor prophylaxis such as Roche’s Hemlibra and, over a longer horizon, gene therapies; Doptelet competes in a separate platelet-disorder market where incumbent therapies and payer decisions matter. These are exposure risks, not evidence of current share loss.

Over the next 1–3 months, the main catalysts are the full report’s product-level trends, guidance, margins, and evidence that immunology weakness is stabilizing. Over 6–18 months, the question is whether haematology growth broadens beyond the leading products enough to offset that weakness and any competitive substitution. The release is mildly positive for operating momentum, but the excerpt alone does not establish earnings conversion, valuation upside, or durability. The contrarian risk is treating strong product sales as evidence of broad-based growth before confirming profitability and persistence.

Key Decisions for Investors

• Maintain a constructive but conditional bias on SOBI; avoid chasing solely on the sales headline until the complete report confirms operating-profit and cash-flow conversion.
• For a 1–3 month catalyst trade, consider adding exposure only if the full results support continued product-level demand and management maintains or raises expectations; absent those checks, treat the release as a watch item rather than a standalone buy signal.
• Track Altuvoct and Doptelet sales alongside immunology trends, gross margin, and guidance. A slowdown in the leading haematology products or further deterioration in immunology would falsify the near-term growth thesis.
• Monitor competitive substitution in haemophilia, particularly uptake of non-factor prophylaxis and gene therapies; this is a structural risk to test over 6–18 months, not a basis to assume immediate revenue decline.